Medtech

This year's top 100 ranking of global medtechs by revenue shows how industry leaders are aligning innovation with market trends to meet user and patient needs, while also managing their portfolios for growth.


View Rankings

Medtech Industry Reaches New Chapter In Its Structural Evolution

 
• By Ashley Yeo

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

 
• By Ashley Yeo

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Combating Stroke Requires Global Health Systems To Take A Giant Step

 
• By Ashley Yeo

Health authorities around the world are being advised to mitigate the relentless rise in the long-term costs of stroke, set to top $1.5tn within a generation. Wider availability of mechanical thrombectomy will help address providers’ and patients’ needs, Royal Philips CMO Carla Perón explained in an interview with In Vivo.

Dementia Sees The Most Exponential Increase In Chronic Disease Burden

 
• By Ashley Yeo

Josef Coresh, founding director of the Optimal Aging Institute at NYU Grossman School of Medicine, talks about his ongoing research to mark Alzheimer’s and Brain Awareness Month.

MTI 100 Company Rankings

Medtech Insight’s MTI 100 comprises a set of industry league tables providing US dollar rankings of medtech companies according to their overall annual medical device and IVD revenues where appropriate, and product sector-specific revenues where possible.

The 2023 MTI 100 list reflects a below-average level of M&A activity. The threshold for inclusion rose to half a billion US dollars for the first time. Several new names – many of them China-based IVD and other medical device manufacturers – have entered the lower reaches of the Top 100.

The table also reflects the winding out of COVID-based revenues, especially among IVD players – with the top ten companies Abbott and Roche the most visible examples of this.

Industry restructuring for faster growth and shareholder value creation predominate the thoughts of the leading players, and also many of those lower down the Top 100 ranking who are seeking rapidly to exploit the transformation of healthcare delivery, be it a place-based shift or by means of technology-driven innovations that are increasingly AI-enabled.

Figures shown are for the year ended 31 December 2023, except where noted, while most Japanese companies’ 31 March 2024 year-ends are reflected.

Unless noted, the Top 100 and key industry subsector tables show reported external medtech-specific sales values of publicly owned companies at manufacturer level and exclude service revenues unless noted. Average annual exchange US dollar exchange rates from 31 December 2023 are used for comparative purposes, regardless of the company’s financial year end.

For more information contact Ashley.Yeo@citeline.com